OPKO Health Inc traded at 360.50 this Friday March 13th, decreasing 2.10 or 0.58 percent since the previous trading session. Looking back, over the last four weeks, OPKO Health lost 4.38 percent. Over the last 12 months, its price fell by 43.04 percent. Looking ahead, we forecast OPKO Health Inc to be priced at 349.61 by the end of this quarter and at 318.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
OPKO Health, Inc. is a healthcare company. Its segments include Diagnostics and Pharmaceutical. The Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP, hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.